Global Pharmaceutical Excipients for Non-injection Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Pharmaceutical Excipients for Non-injection Market Research Report 2024
Pharmaceutical excipients are the inactive substances that are added to a drug formulation to improve its stability, bioavailability, palatability, and other properties. They are generally regarded as safe (GRAS) by regulatory agencies and are used in various dosage forms, such as tablets, capsules, oral liquids, topical creams, and inhalers.
According to MRAResearch’s new survey, global Pharmaceutical Excipients for Non-injection market is projected to reach US$ 8997.9 million in 2033, increasing from US$ 4682 million in 2022, with the CAGR of 9.7% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Pharmaceutical Excipients for Non-injection market research.
Key manufacturers engaged in the Pharmaceutical Excipients for Non-injection industry include Dow, Nippon Fine Chemical, Nanjing Well Pharmaceutical, Jiangsu Maxim Biological, NOF, Croda, Jiangsu Poly Pharmaceutical, Er Kang Pharmaceutical and Guangzhou Hanfang Pharmaceutical, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Pharmaceutical Excipients for Non-injection were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Pharmaceutical Excipients for Non-injection market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Pharmaceutical Excipients for Non-injection market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Dow
Nippon Fine Chemical
Nanjing Well Pharmaceutical
Jiangsu Maxim Biological
NOF
Croda
Jiangsu Poly Pharmaceutical
Er Kang Pharmaceutical
Guangzhou Hanfang Pharmaceutical
Pfanstiehl
Xi'an Libang Pharmaceutical
Zhejiang Tianyushan Medicinal Oil
Segment by Type
Binders
Disintegrants
Lubricants
Fillers
Others
Tablets
Capsules
Oral Liquids
Others
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Pharmaceutical Excipients for Non-injection report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to MRAResearch’s new survey, global Pharmaceutical Excipients for Non-injection market is projected to reach US$ 8997.9 million in 2033, increasing from US$ 4682 million in 2022, with the CAGR of 9.7% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Pharmaceutical Excipients for Non-injection market research.
Key manufacturers engaged in the Pharmaceutical Excipients for Non-injection industry include Dow, Nippon Fine Chemical, Nanjing Well Pharmaceutical, Jiangsu Maxim Biological, NOF, Croda, Jiangsu Poly Pharmaceutical, Er Kang Pharmaceutical and Guangzhou Hanfang Pharmaceutical, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Pharmaceutical Excipients for Non-injection were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Pharmaceutical Excipients for Non-injection market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Pharmaceutical Excipients for Non-injection market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Dow
Nippon Fine Chemical
Nanjing Well Pharmaceutical
Jiangsu Maxim Biological
NOF
Croda
Jiangsu Poly Pharmaceutical
Er Kang Pharmaceutical
Guangzhou Hanfang Pharmaceutical
Pfanstiehl
Xi'an Libang Pharmaceutical
Zhejiang Tianyushan Medicinal Oil
Segment by Type
Binders
Disintegrants
Lubricants
Fillers
Others
Segment by Application
Tablets
Capsules
Oral Liquids
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Pharmaceutical Excipients for Non-injection report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source